Colterol is a short-acting β2-adrenoreceptor agonist. Bitolterol, a prodrug for colterol,[1] is used in the management of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD).

Colterol
Clinical data
Other namesN-tert-Butylarterenol; N-tert-Butylnoradrenaline
Identifiers
  • 4-[2-(tert-Butylamino)-1-hydroxyethyl]benzene-1,2-diol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H19NO3
Molar mass225.288 g·mol−1
3D model (JSmol)
  • CC(C)(C)NCC(C1=CC(=C(C=C1)O)O)O
  • InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-5-9(14)10(15)6-8/h4-6,11,13-16H,7H2,1-3H3
  • Key:PHSMOUBHYUFTDM-UHFFFAOYSA-N

Patents:[2][3]

References

edit
  1. ^ Walker SB, Kradjan WA, Bierman CW (6 May 1985). "Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma". Pharmacotherapy. 5 (3): 127–37. doi:10.1002/j.1875-9114.1985.tb03410.x. PMID 3895171. S2CID 29431526.
  2. ^ Aktiengesellschaft F Hoffmann, CH263801 (1949-09-15 to Hoffmann La Roche).
  3. ^ Yasuo Konishi, Joanne Magoon, Suwatchai Jarussophon, WO2008092257 (2008 to National Research Council Of Canada). Location in patent: Page column 17.